We first demonstrated that treating suspended LLC cells with PS inhibited the binding of a soluble DPP IV (31–767) peptide possessing FN-binding ability [26] to polyFN (Fig. 4a), entertaining the possibility that PS could prevent circulatory tumor cells from adhering to the lung vasculature. The gene discussed is DPP4; the disease is neoplasm.